FDA says Vital Health & Wellness sold Holy Tea as an unapproved drug with disease-treatment claims.
What happened
FDA inspected the tea processing facility in Trenton, TN, on August 23 and 30, 2021, and collected the label for Dr. Miller’s Holistic Premium Holy Tea. FDA also reviewed the company’s website in November 2021 and February 2022. It found label and website claims that the tea is intended to treat diseases such as acid reflux, high blood pressure, liver disorders, HIV/AIDS, and cancer, making it an unapproved new drug and misbranded.
What FDA found
The product label claims the tea may be beneficial for acid reflux and high blood pressure, which shows it is intended to treat diseases.
FD&C Act § 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]The website’s ingredient and cancer pages claim tea ingredients treat conditions such as high blood pressure, liver disease, HIV/AIDS, cancer, and infections, which also shows drug intended use.
FD&C Act § 201(g)(1)(B) [21 U.S.C. 321(g)(1)(B)]Because the tea is not generally recognized as safe and effective for these uses, it is a new drug that requires FDA approval before sale.
FD&C Act §§ 201(p), 301(d), 505(a) [21 U.S.C. 321(p), 331(d), 355(a)]The product is misbranded because it lacks adequate directions for safe use by a layperson for its intended disease uses.
FD&C Act § 502(f)(1) [21 U.S.C. 352(f)(1)]Selling the misbranded drug in interstate commerce violates the Act.
FD&C Act § 301(a) [21 U.S.C. 331(a)]
What FDA wants
Notify FDA in writing within 15 working days of receipt of the letter of the specific steps taken to address the violations and prevent recurrence, including related documentation. If corrective actions cannot be completed within 15 working days, state the reason for the delay and the time within which they will be done.
Who should pay attention
- herbal tea and supplement brands that make disease-related claims
- online retailers selling supplement or tea products
- regulatory and labeling reviewers for food and supplement companies
This is a summary. Read the original letter on fda.gov.